MBX Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
MBX Biosciences, Inc. (MBX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 231.77 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-06
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 39.98K shares, a 33.63% decline year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 191.79K shares, a 65.03% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 31.71K shares.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 17.07K shares.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 225.23K shares, a 19.30% increase from fiscal 2024.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 188.79K shares, a 11.27% decline from fiscal 2023.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 212.75K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 39.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 231.77K shares 10-Q · filed 2026-08-06 | 263.48K shares derived: sum of 3 quarters · filed 2026-08-06 | 280.55K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 191.79K shares 10-Q · filed 2026-05-07 | 223.50K shares derived: sum of 2 quarters · filed 2026-05-07 | 240.57K shares derived: sum of 3 quarters · filed 2026-05-07 | 300.80K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 31.71K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 48.78K shares derived: sum of 2 quarters · filed 2026-03-12 | 109.01K shares derived: sum of 3 quarters · filed 2026-03-12 | 225.23K shares 10-K · filed 2026-03-12 |
| 2025-09-30 | 17.07K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 77.30K shares derived: sum of 2 quarters · filed 2025-11-06 | 193.52K shares 10-Q · filed 2025-11-06 | 183.61K shares derived: sum of 4 quarters · filed 2026-03-12 |
| 2025-06-30 | 60.23K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 176.45K shares 10-Q · filed 2025-08-07 | 166.54K shares derived: sum of 3 quarters · filed 2026-03-12 | |
| 2025-03-31 | 116.22K shares 10-Q · filed 2025-05-12 | 106.31K shares derived: sum of 2 quarters · filed 2026-03-12 | ||
| 2024-12-31 | -9.91K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | 188.79K shares 10-K · filed 2026-03-12 | ||
| 2024-09-30 | 198.70K shares 10-Q · filed 2024-11-07 | |||
| 2023-12-31 | 212.75K shares 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |